Trailing-twelve-month (TTM) revenue is $249.72 Million with a year-over-year growth of +3.04%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2026Period ended 2025-09-30 | $60,737,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q3 FY2026Period ended 2025-12-31 | $65,126,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-03 |
| Q4 FY2026Period ended 2026-03-31 | $63,724,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-03 |
| Q1 FY2027Period ended 2026-06-30 | $60,138,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-10 |
| TTM revenue | $249,725,000 |
Current P/S: $759,023,536 market capitalization ÷ $249,725,000 TTM revenue = 3.04x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T18:55:10.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q1 FY2027 (2026-06-30): $60.14M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T18:57:43.719Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-03-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-03-31 · USD | FY20222022-03-31 · USD | FY20232023-03-31 · USD | FY20242024-03-31 · USD | FY20252025-03-31 · USD | FY20262026-03-31 · USD |
|---|---|---|---|---|---|---|
| Biopharmaceutical Development | N/A | N/A | N/A | $41M | N/A | $49M |
| Calibration Solutions | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-03-31 · USD | FY20222022-03-31 · USD | FY20232023-03-31 · USD | FY20242024-03-31 · USD | FY20252025-03-31 · USD | FY20262026-03-31 · USD |
|---|---|---|---|---|---|---|
| CHINA | N/A | N/A | $26M | $25M | $25M | $20M |
| Non-US | $63M | $85M | N/A |
$249.72M
$249.72 Million
+3.04%
vs. $242.36M a year ago (TTM)
+12.45%
5 Year compound annual growth rate
1 Year
+3.04%
3 Year
+4.43%
5 Year
+12.45%
10 Year
+11.04%
15 Year
+14.16%
20 Year
+16.01%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $249.13M | +$8.15M | +3.38% |
| 2025 | $240.98M | +$24.79M | +11.47% |
| 2024 | $216.19M | ($2.89M) | (1.32%) |
| 2023 | $219.08M | +$34.74M | +18.85% |
| 2022 | $184.34M | +$50.40M | +37.63% |
| 2021 |
TTM Growth
+3.04%
3-Year CAGR
+4.43%
5-Year CAGR
+12.45%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T18:57:43.719Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
2026-03-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| $48M |
| N/A |
| $54M |
| Clinical Genomics | N/A | N/A | N/A | $53M | N/A | $45M |
|---|
| Product | $107M | $149M | $181M | N/A | $198M | N/A |
|---|
| Service | N/A | N/A | $39M | N/A | $43M | N/A |
|---|
| Sterilization and Disinfection Control | N/A | N/A | N/A | $75M | N/A | $102M |
|---|
| N/A |
| N/A |
| Other | N/A | N/A | $76M | $85M | $99M | $112M |
|---|
| UNITED STATES | $71M | $99M | $117M | $106M | $117M | $117M |
|---|
| $133.94M |
| +$16.25M |
| +13.81% |
| 2020 | $117.69M | +$14.55M | +14.11% |
| 2019 | $103.14M | +$6.96M | +7.23% |
| 2018 | $96.18M | +$2.51M | +2.68% |
| 2017 | $93.67M | +$9.01M | +10.64% |
